Lab21 Limited has won the BioNow Biomedical Project of the Year Award for its MycAssay product line. The BioNow Biomedical Project of the Year Award recognises individuals or organisations who have demonstrated an innovative solution to a specific industry problem.
Lab21’s MycAssay Aspergillus and MycAssay Pneumocystis are the world’s first commercial PCR assays for pulmonary fungal infections. A recent evaluation of MycAssay Aspergillus has shown it to be a sensitive and specific molecular test for the diagnosis of invasive aspergillus.
Hayden Jeffreys, Divisional Director of Products, Lab21 said: “This award for the MycAssay product line recognises the importance of Lab21’s tests for Aspergillus and Pneumocystis, the first products in what is rapidly becoming a portfolio of real-time PCR tests for serious invasive fungal diseases We are pleased with the adoption of these assays into routine use, already demonstrated by increasing sales into 14 countries.”